KRM AYURVEDA LTD
(Formerly Known as KRM Ayurveda Private Limited)

10th August, 2026

SYMBOL: KRMAYURVED

To
The Manager
National Stock Exchange of India Ltd.
Exchange Plaza, Bandra Kurla Complex,
Bandra East Mumbai- 400 051

Sub: Submission of Presentation on the Un-Audited Standalone Financial Results for the quarter ended June 30, 2026.

Dear Sir/Ma'am,

Pursuant to the applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit the Presentation on the Unaudited Standalone Financial Results of the Company for the quarter ended June 30, 2026.

The said presentation is enclosed herewith for your information and records.

We request you to kindly take the above information on record.

Thank you,

For KRM Ayurveda Limited
(Formerly known as KRM Ayurveda Private Limited)

Sanchit Hans
Digitally signed by Sanchit Hans
Date: 2026.08.10 18:10:13 +05'30'

Sanchit Hans
Whole-Time Director
DIN: 09228549

Encl: a/a

Regd. Off. : A-16, G.T. KARNAL ROAD, INDUSTRIAL AREA,
NORTH WEST DELHI-110033
Website: www.krmayurveda.com
Email: hrhead@krmayurveda.com
account1@krmayurveda.com
Contact: +91-9667791365
CIN: L24239DL2019PLC354658

KRM AYURVEDA LIMITED

Q1 FY27 Results

Quarter ended 30 June 2026 · Integrated Ayurvedic healthcare & wellness

TOTAL INCOME

3,286.55

₹ Lakhs

+32.4% YoY +1.4% QoQ

EBITDA

1,256.07

₹ Lakhs

+97.4% YoY +12.4% QoQ

NET PROFIT (PAT)

908.45

₹ Lakhs

+124.2% YoY +16.3% QoQ

EBITDA MARGIN

38.22%

of total income

+1,257 bps YoY +372 bps QoQ

Q1 FY27 Financial Performance

₹ Lakhs

Particulars	Q1 FY27	Q1 FY26	YoY	Q4 FY26	QoQ
Revenue from Operations	3,232.26	2,466.64	+31.0%	3,221.42	+0.3%
Other Income	54.29	14.99	+262.2%	18.67	+190.8%
Total Income	**3,286.55**	**2,481.63**	+32.4%	**3,240.09**	+1.4%
Total Expenses	2,063.06	1,939.49	+6.4%	2,216.72	– 6.9%
EBITDA	**1,256.07**	**636.44**	+97.4%	**1,117.74**	+12.4%
EBITDA Margin	38.22%	25.65%	+1,257 bps	34.50%	+372 bps
Profit Before Tax	1,223.49	542.14	+125.7%	1,023.37	+19.6%
Net Profit (PAT)	**908.45**	**405.28**	+124.2%	**780.98**	+16.3%
PAT Margin	27.64%	16.33%	+1,131 bps	24.10%	+354 bps

Additions in Current Year till date

Hospitals added 2

Clinics added 1

Beds added 103

PROFITABILITY

EBITDA & PAT — Q1 Growth

Year-on-year against Q1 FY26 and sequential against Q4 FY26 · ₹ Lakhs

Q1 YEAR-ON-YEAR

Q1 FY26 → Q1 FY27



EBITDA growth	**+97.4%**
PAT growth	**+124.2%**

Q1 QUARTER-ON-QUARTER

Q4 FY26 → Q1 FY27



EBITDA growth	**+12.4%**
PAT growth	**+16.3%**

38.22%

EBITDA MARGIN

Highest in five quarters; +1,257 bps YoY, +372 bps QoQ

27.64%

PAT MARGIN

+1,131 bps YoY and +354 bps QoQ on operating leverage

CORE FOCUS AREA

Hospital & Services — Capacity-Led Growth

Incremental beds converting to revenue as new facilities ramp up · ₹ Lakhs

SERVICES REVENUE TREND

Q1 FY26 → Q1 FY27

₹ 2,392.20 L

Q1 FY27 SERVICES REVENUE

+109.8% YoY · +45.6% QoQ

₹ 5,468 L

FY26 SERVICES REVENUE

Doubled over FY25 (+100.2%)

Facility Maturity Model

Target utilisation ramp for a new facility

SITE SELECTION DISCIPLINE

- New facilities opened only in catchments that can support a rapid utilisation build-up
- Existing brand pull and physician network shorten the ramp curve
- Incremental beds therefore convert to revenue within the same financial year

OCCUPANCY HEADROOM

Incremental annualised IPD revenue potential from the incremental beds is of around

Rs. 25 cr.

Based on addition of 103 beds till date in FY 27

PRODUCT BUSINESS

Owned D2C Platform Goes Live in Q2 FY27

PRODUCT REVENUE BY QUARTER



₹ 4,701 L

FY26 PRODUCT REVENUE

Broadly stable vs ₹ 4,923 L in FY25

8 Lakh+

YOUTUBE FOLLOWERS

Owned audience across three channels

Q2 FY27 Channel Launch

Planned

Own e-commerce platform

Direct-to-consumer storefront scheduled to go live in Q2 FY27

1mg & national marketplaces

Listings on 1mg and other leading platforms

GMP & ISO certified supply

In-house manufacturing at Kundli, Haryana supports scale-up

OTC & D2C range

Capsules, tablets, syrups and oils across kidney, liver, skin and wellness
Disease specific kits

WHY IT CHANGES THE TRAJECTORY

- Selling direct to patients through own Hospitals and clinics saves marketing expense
- Marketplace listings open national reach well beyond current territories
- An 8 lakh-strong digital audience gives the platform a warm start
- Consumer-led demand should smooth the quarterly phasing seen in bulk ordering